Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine

PFIZER said there were no safety concerns : nearly 95% protection

The vaccine against Sars-Cov-2 developed by Pfizer / BioNTech has completed phase 3 tests on 43,500 volunteers, resulting 95% effective in preventing the onset of symptoms (and therefore disease), even in the elderly. Encouraging latest news, even more than the intermediate results – communicated in recent days – had suggested, according to which the effectiveness could be estimated at around 90%. Furthermore, the vaccine in question did not cause serious side effects in volunteers enrolled in the United States and five other countries. The two companies communicate it, illustrating the results of completing phase 3 of the tests.

In the meantime, we remind you to protect OURSELVES AND OTHERS #socialdistancing #1meter and the importance of using the #mask

We always #staypositive and beautiful, rediscover the smile with our #Deaffriendlyfacemask in #silk100% they are #washablemasks and #doublelayermasks

Discover them here: https://www.cleofefinati.com/mascherine/

LINK BLOG: https://www.corriere.it/salute/malattie_infettive/20_novembre_18/vaccino-covid-pfizer-biontech-efficace-effetti-collaterali-1edd1522-2998-11eb-884f-3aae855c458a.shtml

#coronavirus #covid-19 #pandemia, #pandemia2020  #coronavirusitalia #lockdown #confinementcooking #noicisiamo #ministerodellasalute  #protezionecivile  #crocerossaitaliana   #oms pulsossimetro #pfizer #vaccino #vaccine #cleofefinati #madeinitaly #prudenza  #responsabilità #responsibility #staybrave

Share on:

Leave a Reply

Your email address will not be published.

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.